Launch of AIDD4H, Artificial Intelligence Labcom to discover new drugs

Bourgogne-Franche-Comté University, Oncodesign and SATT Sayens have announced the launch of a joint laboratory (LabCom), created by CIAD Laboratory (University of Burgundy and University of Technology of Belfort-Montbéliard) and biopharmaceutical company Oncodesign. Labcom “AIDD4H” (Artificial Intelligence in Drug Discovery for Health), dedicated to personalized medicine in oncology, is the first step towards creating an open innovation campus with an international focus on the use of artificial intelligence (AI) in medicine. Discovery

Created in 2015, the University of Burgundy Franche-Comté (UBFC) is a university and institutional community (COMUE) that brings together seven higher education and research institutions. It provides quality multidisciplinary training related to research in agro-food, microtechnology, energy and mobility. In addition to these regional economic activities, UFBC is recognized internationally for 3 scientific fields:

  • Advanced materials, wave and intelligent systems,
  • Region, environment, food,
  • Unique and integrated care.

CIAD (Knowledge and Distributed Artificial Intelligence) Laboratory Hall is one of its laboratories. With approximately 70 people (teachers-researchers, doctoral students, engineers, post-doctoral students, administrative staff), its goal is to hybridize, distribute and design interpretable artificial intelligence.


Oncodesign, created in 1995, is located in Disney, within the University and Hospital Center and in the Paris-Sacle cluster. Oncodesign has 230 employees in 3 business units: Services, Biotech, Artificial Intelligence and its affiliates in Canada and Canada. United States. The goal of this biopharmaceutical company, which specializes in precision medicine, is to discover effective therapies to fight cancer and other diseases without therapeutic solutions. It has more than 1,000 customers, including the world’s largest pharmaceutical companies, and relies on a unique technological platform that combines artificial intelligence, pharmaceutical chemistry, pharmacology, regulatory bioanalysis and state-of-the-art medical imaging.


Created in 2013, SAYENS is a catalyst for innovation for companies and market access, a source of growth and job creation.
Researchers and companies, as well as committed to the future of science innovation, have gained access to the skills of 6,500 researchers, 4,000 doctoral students from 140 public research laboratories spread across the SAYENS Grand East region (Lauren and South Champagne Arden-Troyes) and Burgundy-France.

AIDD4H Generic AI Labcom

The goal of AIDD4H is to identify and validate new therapeutic targets and new mechanisms of action in the development of innovative treatments for precise drugs in oncology. Labeled by the Medicine Competitive Cluster, the project is based on a collaboration between CIAD Laboratory and Oncodesign. This joint laboratory was created following the call for Labcom 2020 projects SATT Sayens has coordinated and supported this assembly, thanks to the expertise of its R&D engineers and its intellectual property experts, in its deployment and in the realization of its technical roadmap. Catherine Guillemin, President of Science, has announced:

“Thanks to this joint AIDD4H laboratory, we are very pleased to be able to contribute to the development of innovative solutions to address the challenges of digital health and accelerate future drug transformation.”

Dominic Gravy, President of UBFC, added:

“This joint laboratory is a good illustration of the university’s regional roots and represents an important challenge: accelerating the discovery of molecules by integrating artificial intelligence methods for AIDD4H data processing. “

AI in tackling the challenge of inventing new drugs

Bringing new drugs to market is a long-term task: within the moment when the therapeutic goal is set on which research work can be started, then developed and finally verified, it can take 12 to 15 years. Its research is very expensive, some drugs are abandoned (1 drug will be retained by FDA-EMA authorities for the synthesis of 10,000 molecules). Artificial intelligence is reliable and makes it possible to optimize the choice of molecules by absorbing data in a much faster way.

Philip Gain, CEO of Oncodesign, says:

“We have historically worked with public research actors in our region. We are pleased to establish a new partnership with CIAD Laboratory. AI today, because it multiplies our ability to absorb data, saves time and makes choices more reliable in developing new therapies. The joint AIDD4H laboratory is an accelerator that allows us to integrate AI into the drug discovery process. “

Leave a Comment